The Interplay Between IL‐6, Hepcidin, and BMPR2 Signalling in Pulmonary Arterial Hypertension: Mechanistic Insights Into Vascular Remodelling
Pulmonary Circulation · 2026-04 · 16 (2)
DOI: 10.1002/pul2.70272 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pulmonary Circulation, online erschienen am 05.04.2026. Verfasst von Quezia K Toe und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Imperial College London National Heart and Lung Institute London UK. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation.
Abstract (Originalsprache)
Pulmonary arterial hypertension (PAH) is characterized by excessive pulmonary vasoconstriction and vascular remodelling, with mutations in bone morphogenetic protein receptor type 2 (BMPR2) being the most common genetic alteration associated with the disease. While inflammatory mediators like interleukin‐6 (IL‐6) and the iron‐regulatory hormone hepcidin have been implicated in vascular remodelling, their interaction with BMPR2 signalling remains poorly understood. This study investigated how IL‐6 and hepcidin influence BMPR2 expression and downstream signalling in human pulmonary arterial endothelial cells (hPAECs). Using qPCR and Western blot analyses, we demonstrated that both IL‐6 and hepcidin significantly reduced BMPR2 mRNA and protein levels in hPAECs. Intriguingly, despite this reduction, SMAD1/5 phosphorylation remained active, suggesting compensatory signalling through alternative receptor complexes. Treatment with IL‐6 and hepcidin upregulated inhibitors of differentiation (ID) protein expression, mimicking the effects observed with BMPR2 knockdown. These findings reveal a novel regulatory axis involving IL‐6, hepcidin, and BMPR2 in PAH pathogenesis, where IL‐6 and hepcidin promote vascular remodelling through both BMPR2‐dependent and independent mechanisms. These results suggest that therapeutic strategies targeting this axis, particularly those aimed at rebalancing BMP/TGF‐β signalling, may hold promise for treating PAH.
Autor:innen und Institutionen
- Faculty of Medicine, Imperial College London National Heart and Lung Institute London UK.
- Adult Centre for Pulmonary Hypertension Royal Brompton Hospital London UK.
ORCID-Profile: Quezia K Toe, Theo Issitt
Förderung
- British Heart Foundation
Zitieren
APA
Toe, Q. K., Issitt, T., Quinlan, G. J., & John Wort, S. (2026). The Interplay Between IL‐6, Hepcidin, and BMPR2 Signalling in Pulmonary Arterial Hypertension: Mechanistic Insights Into Vascular Remodelling. Pulmonary Circulation, 16(2). https://doi.org/10.1002/pul2.70272
Vancouver
Toe QK, Issitt T, Quinlan GJ, John Wort S. The Interplay Between IL‐6, Hepcidin, and BMPR2 Signalling in Pulmonary Arterial Hypertension: Mechanistic Insights Into Vascular Remodelling. Pulmonary Circulation. 2026;16(2). doi:10.1002/pul2.70272
BibTeX
@article{Toe2026,
author = {Toe, Quezia K and Issitt, Theo and Quinlan, Gregory J and John Wort, S},
title = {The Interplay Between IL‐6, Hepcidin, and BMPR2 Signalling in Pulmonary Arterial Hypertension: Mechanistic Insights Into Vascular Remodelling},
journal = {Pulmonary Circulation},
year = {2026},
volume = {16},
number = {2},
doi = {10.1002/pul2.70272}
}
EUVIMED